In a recent actualization of the International Consensus Classification (ICC) 2022 AML and the World Health Organization (WHO) 2022 classification, TP53 mutant (TP53mut) AML and myelodysplastic syndromes (MDS) have been individualized based on their poor prognosis [33,34]. The gene discussed is TP53; the disease is acute myeloid leukemia.